Original Research
Published on 23 Oct 2023
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy
in B Cell Biology
- 13,235 views
- 20 citations





















